<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941549</url>
  </required_header>
  <id_info>
    <org_study_id>DS102A-02</org_study_id>
    <nct_id>NCT02941549</nct_id>
  </id_info>
  <brief_title>Safety And Efficacy Study Of Orally Administered DS102 In Patients With NAFLD</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In Patients With NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afimmune</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to
      assess the safety and efficacy of orally administered DS102 capsules versus placebo in the
      treatment of adult patients with Non Alcoholic Fatty Liver Disease (NAFLD)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum ALT (alanine aminotransferase) from baseline to week 16</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs) in each treatment group leading to discontinuation</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will receive matching placebo capsules twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg DS102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive 500 mg DS102 capsules twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mg DS102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive 1000 mg DS102 capsules twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS102</intervention_name>
    <arm_group_label>500 mg DS102</arm_group_label>
    <arm_group_label>1000 mg DS102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with NAFLD by the presence of hepatic steatosis on imaging or
             histology in the absence of any secondary causes

          -  Patients with an ALT ≥ 1.5 ULN and &lt; 5 ULN on two occasions 7 or more days apart
             during screening

          -  Patients with a body mass index (BMI) between 25.0 and 40.0 kg/m² inclusive. Patients
             with a history of controlled obesity or controlled diabetes are allowed on the study

          -  Patients aged between 18 and 75 years inclusive

        Exclusion Criteria:

          -  Patients with an unstable metabolic condition such as weight change &gt; 5% in the 3
             months prior to inclusion

          -  Patients with medical/surgical history of gastric bypass surgery, orthotopic liver
             transplant (OLT) or listed for OLT

          -  Patients with uncontrolled diabetes mellitus type 2, i.e. HbA1c ≥ 9% (75 mmol/mol) at
             the time of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Newsome, B.Sc, MBChB, FRCPE, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Lumsden, Ph.D</last_name>
    <phone>0035312998382</phone>
    <email>robert.lumsden@afimmune.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

